A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a monoclonal antibody against vascular endothelial growth factor), is standard first-line treatment for metastatic colorectal cancer. Before the introduction of bevacizumab, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) showed superior efficacy as compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI). In a phase 2 study, FOLFOXIRI plus bevacizumab showed promising activity and an acceptable rate of adverse effects.
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
LOUPAKIS, FOTIOS;CREMOLINI, CHIARA;Masi, Gianluca;LONARDI, SARA;SALVATORE, LISA;FALCONE, ALFREDO
2014-01-01
Abstract
A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a monoclonal antibody against vascular endothelial growth factor), is standard first-line treatment for metastatic colorectal cancer. Before the introduction of bevacizumab, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) showed superior efficacy as compared with fluorouracil, leucovorin, and irinotecan (FOLFIRI). In a phase 2 study, FOLFOXIRI plus bevacizumab showed promising activity and an acceptable rate of adverse effects.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
NEJMoa1403108.pdf
accesso aperto
Tipologia:
Versione finale editoriale
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
595.47 kB
Formato
Adobe PDF
|
595.47 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
